Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis

Figures

• 

  Figure 1. Weighted Kaplan–Meier estimates for all-cause mortality comparing (a) macitentan+PDE5i combination versus PDE5i monotherapy and (b) macitentan+PDE5i combination versus macitentan monotherapy. For macitentan+PDE5i combination therapy, all patients were assigned a weight of 1; the number at risk is the average rounded to a full integer of the number of patients who are still at risk over the 57 imputed datasets. For monotherapy groups, patients were re-weighted to balance the characteristics between the monotherapy and combination therapy cohorts; the number at risk is the average rounded to a full integer of the sum of the weights of the patients who are still at risk over the 57 imputed datasets. PDE5i, phosphodiesterase-5 inhibitor.

• 

  Figure 2. Weighted hazard ratios for time to all-cause mortality for macitentan+PDE5i combination therapy versus (a) PDE5i monotherapy and (b) macitentan monotherapy. For macitentan+PDE5i combination therapy and monotherapy unweighted groups, all patients were assigned a weight of 1; the number of patients is the average rounded to a full integer of the number of patients over the 57 imputed datasets. For monotherapy weighted groups, patients were re-weighted to balance the characteristics between the monotherapy and combination therapy cohorts; the number of patients is the average rounded to a full integer of the sum of these weights over the 57 imputed datasets. ESS represents the size of an unweighted sample with approximately the same amount of precision as the weighted sample under consideration. CI, confidence interval; ESS, effective sample size; HR, hazard ratio; PDE5i, phosphodiesterase-5 inhibitor; TP, treatment policy; WOT, while on treatment.

• 

  Figure 3. Weighted hazard ratios for time to the composite of all-cause mortality and all-cause hospitalization for macitentan+PDE5i combination therapy versus (a) PDE5i monotherapy and (b) macitentan monotherapy and weighted Kaplan–Meier estimates for all-cause mortality and all-cause hospitalization for macitentan+PDE5i combination therapy versus (c) PDE5i monotherapy and (d) macitentan monotherapy. CI, confidence interval; ESS, effective sample size; HR, hazard ratio; PDE5i, phosphodiesterase-5 inhibitor; TP, treatment policy; WOT, while on treatment.